Shots:
- The companies will evaluate SpringWorks’ nirogacestat (GSI) + Seagen’s SEA-BCMA (Ab targeting BCMA) in patients with RRMM. The companies anticipate commencement of the study in H2’21
- Seagen to sponsor & conduct a P-I study to evaluate the safety, tolerability, and preliminary efficacy of the combination, and will assume all costs of study, other than the expenses related to the manufacturing of nirogacestat and IP rights
- The companies will form a joint development committee to manage the clinical study. Additionally, SpringWorks is conducting a global P-III DeFi Trial to evaluate nirogacestat as monothx. in adults with progressing desmoid tumors
Click here to read full press release/ article | Ref: Globe Newswire | Image: Neurofibromatosis Network
The post SpringWorks and Seagen Enter into a Clinical Collaboration to Evaluate Nirogacestat + SEA-BCMA for R/R Multiple Myeloma first appeared on PharmaShots.
